HenryRRWiest-KentTAScheafferL. Metabolic consequences of very low-calorie diet therapy in obese non-insulin-dependent diabetic and nondiabetic subjects. Diabetes1986; 35: 155-64.
2.
WingRRKoeskeREpsteinLH. Long-term effects of modest weight loss in type II diabetic patients. Arch Intern Med. 1987; 147: 1749-53.
3.
BaileyCJ. Hypoglycaemic, antihyperglycaemic and antidiabetic Drugs. Diabetic Medicine1992; 9: 482-3.
4.
BaileyCJDaviesMJ. Pharmacological therapy of hypoglycaemia in type 2 diabetes mellitus. In Oxford textbook of endocrinology and diabetes. 2nd ednWassJAHStewartPM eds. Oxford University Press, Oxford. 2011 pp. 1779-95.
PerlmuterLCFlanaganBPShahPHSinghSP. Glycemic control and hypoglycemia. Diabetes Care. 2008; 31: 2072–76.
7.
BaileyCJ. Diabetes: Insulin plus metformin for T2DM—are there benefits?Nature Reviews Endocrinology2012; 8: 449-50.
8.
DowlingRJOGoodwinPJStambolicV. Understanding the benefit of metformin use in cancer treatment. BMC Medicine2011, 9: 33 doi: 10.1186/1741-7015-9-33. http://www.biomedcentral.com/1741-7015/9/33. Acessed January 2013.
ListJFWooVMoralesETangWFiedorekFT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care2009; 32: 650-7.
13.
KomoroskiBVachharajaniNFengY. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther. 2009; 85: 513-9. (Erratum in vol 85 pt5: 558).
14.
WildingJPNorwoodPT’joenC. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care2009; 32: 1656-62.
15.
ZhangLFengYListJ. Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight. Diabetes Obes Metab. 2010; 12: 510-6.
16.
FerranniniERamosSJSalsaliA. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care2010; 33: 2217-24.
17.
BaileyCJGrossJLPietersA. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet2010; 375: 2223-33.
18.
KasichayanulaSChangMHasegawaM. Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus. Diabetes Obes Metab. 2011; 13: 357-65.
19.
StrojekKYoonKHHrubaV. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2011; 13: 928-38.
20.
NauckMADel PratoSMeierJJ. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care2011; 34: 2015-22.
21.
BaileyCJAqbalNT’joenCListJF. Dapagliflozin monotherapy in drug-naive patients with diabetes: a randomized-controlled trial of low-dose range. Diabetes Obes Metab2012: 14: 951-9.
22.
SalsaliARohwedderKMansfieldTA. Durability of dapagliflozin treatment response in patients with T2DM: 2-year results. ADA 2012. Diabetes2012; 61: suppl 1, Abs 1030-P, A264.
23.
BolinderJLjunggrenÖKullbergJ. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab2012; 97: 1020-31.
24.
HenryRRMurrayAVMarmolejoMH. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract. 2012; 66: 446-56.
25.
WildingJPWooVSolerNG, Dapagliflozin 006 Study Group. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012; 156: 405-15.
26.
RosenstockJVicoMWeiL. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care2012; 35: 1473-8.
27.
KasichayanulaSLiuXShyuWC. Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. Diabetes Obes Metab. 2011; 13: 47-54.
28.
KasichayanulaSChangMLiuX. Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin. Adv Ther. 2012; 29: 163-77.
OhtakeYSatoTKobayashiT. Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem. 2012; 55: 7828-40.
34.
FootCPerkovikVNealB. Effects of SGLT2 inhibitors on cardiovascular outcomes. Diabetes Vasc Dis Res. 9:117-23.
